ArchGynecolObstet 2011][Bujan L
All animal experiments followed the animal ethics guidelines and were approved by the Yonsei University Institutional Animal Care and Use Committee, Yonsei University School of Medicine (Seoul, Korea)
The approval of XPOVIO was based upon the efficacy and safety in a prespecified subgroup analysis of the 83 patients whose disease was refractory to bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab, as the benefit-risk ratio appeared to be greater in this more heavily pretreated population than in the overall trial population
Goal: Explore anabolic and metabolic effects driven by sustained IGF-1 receptor activity from this long-acting analog effects studied preclinically and not established in humans [1] [2]
[DOI] [PubMed] [Google Scholar] 59.Kang YA, Choi HR, Na JI, et al